Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

CD33-TIM3 Dual CAR T Cells: Enhancing Specificity While Maintaining Efficacy Against AML

Yingshuai Wang, Wenjie Lu, Lisa Rohrbacher, Heinrich Flaswinkel, Alica Joana Emhardt, Giulia Magno, Sascha Haubner, Sebastian Kobold, Heinrich Leonhardt, Karl-Peter Hopfner, Dirk H Busch, Veit L. Buecklein, Daniel Nixdorf, Marion Subklewe

Blood (2023) 142 (Supplement 1): 3449.

https://doi.org/10.1182/blood-2023-180890

Published: 2023

Journal Articles

Uncovering the Enemy: Single-Cell Transcriptional Profiling of Measurable Residual Disease (MRD) Cells

Maryam Kazerani, Lucas Wange, Benjamin Tast, Maria Solovey, Daniel Nixdorf, Lisa Rohrbacher, Christina Heitmüller, Thomas Koehnke, Frauke Schnorfeil, Victoria V Grunwald, Karsten Spiekermann, Klaus H. Metzeler, Karl-Peter Hopfner, Wolfgang Enard, Veit L Buecklein, Marion Subklewe

Blood (2022) 140 (Supplement 1): 6321–6322.

https://doi.org/10.1182/blood-2022-167788

Published: 2022

Journal Articles

Aberrant Cathepsin S Induces a Supportive Immune Microenvironment in Follicular Lymphoma

Blood (2019) 134 (Supplement_1): 657.

https://doi.org/10.1182/blood-2019-122663

Published: 2019

Journal Articles

Exploiting an Anti-CD3/CD33 Bispecific Antibody to Redirect Donor T Cells Against HLA Loss Leukemia Relapses

Pier Edoardo Rovatti, MD, Laura Zito, MSc, Eleonora Draghi, MSc, Monika Herrmann, PhD, Anetta Marcinek, MSc, Bettina Brauchle, MSc, Cesare Covino, MSc, Mattia Di Bono, MSc, Matteo Giovanni Carrabba, MD, Massimo Bernardi, MD, Karl-Peter Hopfner, PhD, Cristina Toffalori, PhD, Fabio Ciceri, MD, Marion Subklewe, MD, Luca Vago, MD PhD

Blood (2019) 134 (Supplement_1): 513.

https://doi.org/10.1182/blood-2019-126641

Published: 2019

Journal Articles

Evaluation of a Bifunctional Sirpα-CD123 Fusion Antibody for the Elimination of Acute Myeloid Leukemia Stem Cells

Siret Tahk, Saskia Schmitt, Christian Peter Augsberger, Binje Vick, PhD, Laia Pascual Ponce, PhD, Irmela Jeremias, MD PhD, Georg Wittmann, MD, Nadja Fenn, PhD, Marion Subklewe, MD, Karl-Peter Hopfner, PhD

Blood (2019) 134 (Supplement_1): 2544.

https://doi.org/10.1182/blood-2019-128145

Published: 2019

Journal Articles

Bifunctional PD-1 × αCD3 × αCD33 fusion protein reverses adaptive immune escape in acute myeloid leukemia

Monika Herrmann, Christina Krupka, Katrin Deiser, Bettina Brauchle, Anetta Marcinek, Ana Ogrinc Wagner, Felicitas Rataj, Ralph Mocikat, Klaus H. Metzeler, Karsten Spiekermann, Sebastian Kobold, Nadja C. Fenn, Karl-Peter Hopfner, Marion Subklewe

Blood (2018) 132 (23): 2484–2494.

https://doi.org/10.1182/blood-2018-05-849802

Published: 2018

Includes: Supplemental data

Journal Articles

Development of a Bifunctional Checkpoint Inhibitory T Cell Engager (CiTE) to Reverse Adaptive Immune Escape in AML

Monika Herrmann, PhD, Christina Krupka, PhD, Katrin Deiser, PhD, Bettina Lindl, Ralph Mocikat, MD, Klaus H. Metzeler, MD, Karsten Spiekermann, MD, Sebastian Kobold, MD, Nadja Fenn, PhD, Karl-Peter Hopfner, PhD, Marion Subklewe, MD

Blood (2018) 132 (Supplement 1): 4069.

https://doi.org/10.1182/blood-2018-99-119624

Published: 2018

Journal Articles

Exome sequencing identifies recurring FLT3 N676K mutations in core-binding factor leukemia

Blood (2013) 122 (10): 1761–1769.

https://doi.org/10.1182/blood-2013-01-476473

Published: 2013

Includes: Supplemental data

Journal Articles

Exome Sequencing Identifies Recurring FLT3 N676K Mutations in Core Binding Factor Leukemia

Sabrina Opatz, Harald Polzer, Tobias Herold, MD, Nikola P Konstandin, Bianka Ksienzyk, Alexander Graf, Stefan Krebs, PhD, Helmut Blum, PhD, Karl Peter Hopfner, PhD, Purvi M. Kakadia, PhD, Stephanie Schneider, PhD, Annika Dufour, PhD, Jan Braess, MD, Michael Heuser, MD, Wolfgang Hiddemann, MD, PhD, Karsten Spiekermann, MD, Stefan K Bohlander, MD, Philipp A Greif, MD

Blood (2012) 120 (21): 404.

https://doi.org/10.1182/blood.V120.21.404.404

Published: 2012

Journal Articles

GATA2 zinc finger 1 mutations associated with biallelic CEBPA mutations define a unique genetic entity of acute myeloid leukemia

Blood (2012) 120 (2): 395–403.

https://doi.org/10.1182/blood-2012-01-403220

Published: 2012

Includes: Supplemental data

Journal Articles

Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies

Gerhard Niederfellner, Alfred Lammens, Olaf Mundigl, Guy J. Georges, Wolfgang Schaefer, Manfred Schwaiger, Andreas Franke, Kornelius Wiechmann, Stefan Jenewein, Jerry W. Slootstra, Peter Timmerman, Annika Brännström, Frida Lindstrom, Ekkehard Mössner, Pablo Umana, Karl-Peter Hopfner, Christian Klein

Blood (2011) 118 (2): 358–367.

https://doi.org/10.1182/blood-2010-09-305847

Published: 2011

Includes: Multimedia, Supplemental data

Journal Articles

Crystal Structure Analysis Reveals That the Novel Type II Anti-CD20 Antibody GA101 Interacts with a Similar Epitope as Rituximab and Ocrelizumab but in a Fundamentally Different Way.

Gerhard J Niederfellner, Alfred Lammens, Manfred Schwaiger, Guy Georges, Kornelius Wiechmann, Andreas Franke, Wolfgang Schaefer, Stefan Jenewein, Jerry Slootstra, Ekkehard Moessner, Pablo Umana, Karl-Peter Hopfner, Christian Klein

Blood (2009) 114 (22): 3726.

https://doi.org/10.1182/blood.V114.22.3726.3726

Published: 2009

Journal Articles

Point mutations in the juxtamembrane domain of FLT3 define a new class of activating mutations in AML

Carola Reindl, Ksenia Bagrintseva, Sridhar Vempati, Susanne Schnittger, Joachim W. Ellwart, Katja Wenig, Karl-Peter Hopfner, Wolfgang Hiddemann, Karsten Spiekermann

Blood (2006) 107 (9): 3700–3707.

https://doi.org/10.1182/blood-2005-06-2596

Published: 2006

Journal Articles

Point Mutations Found in the Juxtamembrane Domain of FLT3 Define a New Class of Activating Mutations in AML.

Carola Reindl, Ksenia Bagrintseva, Susanne Schnittger, Joachim W. Ellwart, Katja Wenig, Karl-Peter Hopfner, Wolfgang Hiddemann, Karsten Spiekermann

Blood (2005) 106 (11): 4388.

https://doi.org/10.1182/blood.V106.11.4388.4388

Published: 2005

NARROW

CD33-TIM3 Dual CAR T Cells: Enhancing Specificity While Maintaining Efficacy Against AML

Uncovering the Enemy: Single-Cell Transcriptional Profiling of Measurable Residual Disease (MRD) Cells

Aberrant Cathepsin S Induces a Supportive Immune Microenvironment in Follicular Lymphoma

Exploiting an Anti-CD3/CD33 Bispecific Antibody to Redirect Donor T Cells Against HLA Loss Leukemia Relapses

Evaluation of a Bifunctional Sirpα-CD123 Fusion Antibody for the Elimination of Acute Myeloid Leukemia Stem Cells

Bifunctional PD-1 × αCD3 × αCD33 fusion protein reverses adaptive immune escape in acute myeloid leukemia

Development of a Bifunctional Checkpoint Inhibitory T Cell Engager (CiTE) to Reverse Adaptive Immune Escape in AML

Exome sequencing identifies recurring FLT3 N676K mutations in core-binding factor leukemia

Exome Sequencing Identifies Recurring FLT3 N676K Mutations in Core Binding Factor Leukemia

GATA2 zinc finger 1 mutations associated with biallelic CEBPA mutations define a unique genetic entity of acute myeloid leukemia

Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies

Crystal Structure Analysis Reveals That the Novel Type II Anti-CD20 Antibody GA101 Interacts with a Similar Epitope as Rituximab and Ocrelizumab but in a Fundamentally Different Way.

Point mutations in the juxtamembrane domain of FLT3 define a new class of activating mutations in AML

Point Mutations Found in the Juxtamembrane Domain of FLT3 Define a New Class of Activating Mutations in AML.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only